Corneli Paola, Conforti Claudio, Retrosi Chiara, Vezzoni Roberta, di Meo Nicola, Piccolo Vincenzo, Farinazzo Eleonora, Russo Teresa, Magaton Rizzi Giovanni, Giuffrida Roberta, Zalaudek Iris
Dermatology Unit, Maggiore Hospital Trieste, University of Trieste, Trieste, Italy.
Dermatology Unit, Second University of Naples, Naples, Italy.
Dermatol Ther. 2020 Mar;33(2):e13250. doi: 10.1111/dth.13250. Epub 2020 Feb 20.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent nonmelanoma skin cancer (NMSC). The majority of in situ cSCC [cSCC (Tis)] can be cured surgically, while local advanced and metastatic ones require other treatments, but there are no therapies approved by U.S. Food and Drug Administration (FDA). Available treatments for these stages included radiotherapy, chemotherapy as cisplatin, but responses to these treatments are usually of short duration. Programmed death-1 (PD-1) inhibitors (pembrolizumab, nivolumab, and cemiplimab) are an innovative immunologic treatment that now has been shown to be useful for the treatment of advanced cSCC. Nowadays, data about the response rate with the use of PD-1 inhibitors in cSCC are still few and, especially, the duration of the response after the start of treatment is short. Moreover, the number of cases is too small to express the beneficial effects of these treatments, although most data reported in the literature show quite good response rates. This review focused on some of the studies and associated results through an interesting research on search engines of all the cases about these systemic drugs, analyzing effects and side effects, and the research has been conducted considering published cases since March 2016 to October 2019.
皮肤鳞状细胞癌（cSCC）是第二常见的非黑色素瘤皮肤癌（NMSC）。大多数原位cSCC [cSCC（Tis）]可通过手术治愈，而局部晚期和转移性cSCC则需要其他治疗方法，但尚无美国食品药品监督管理局（FDA）批准的疗法。这些阶段的可用治疗方法包括放疗、以顺铂为主的化疗，但这些治疗的反应通常持续时间较短。程序性死亡-1（PD-1）抑制剂（帕博利珠单抗、纳武利尤单抗和西米普利单抗）是一种创新的免疫治疗方法，现已证明对晚期cSCC的治疗有效。如今，关于在cSCC中使用PD-1抑制剂的反应率的数据仍然很少，尤其是治疗开始后的反应持续时间较短。此外，尽管文献中报道的大多数数据显示反应率相当不错，但病例数量太少，无法体现这些治疗的有益效果。本综述通过在搜索引擎上对所有关于这些全身药物的病例进行有趣的研究，重点关注了一些研究及相关结果，分析了其疗效和副作用，研究涵盖了2016年3月至2019年10月期间发表的病例。
